

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Zucali, Paolo Andrea

eRA COMMONS USER NAME (credential, e.g., agency login): pzucali

POSITION TITLE: Head, Uroncological Tumors and Rare Tumors of the Chest Unit

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
Faculty of Medicine and Surgery, University of Milan, Milan	MD	03/1997	Medicine
Medical Oncology Degree, University of Milan, Milan	OTH	11/2002	Medical Oncology

A. Personal Statement

Prof. Paolo Andrea Zucali completed his Medical Degree and residency in Medical Oncology at the Medical School of the University of Milan (Italy). He is Head of tumors of the genito-urinary tract and rare tumors of the chest (thymic epithelial tumors and pleural tumors), and Associate Professor of Medical Oncology, Department of Biomedical Sciences, Humanitas University (HUNIMED), Pieve Emanuele (Milano), Italy. Prof. Zucali (Scopus Author ID: 6505796979 - ORCID ID: <http://orcid.org/0000-0002-2274-1702>) has a longstanding research interest and co-authored 180 publications in peer-reviewed journals, with a Raw Impact Factor of 1377,691, and Total H-index (Scopus) of 44. His publications have had 6094 citations (Scopus). He has a long-standing interest in the field of clinical and translational cancer research with a focus on chest rare tumors (thymic epithelial tumors and pleural tumors). He participated as P.I., co-P.I., member of the Steering Committee in more than 130 national and international translational and clinical trials (phase 1-2-3) of new drugs (small molecules, monoclonal antibodies, chemotherapy, immuno-oncology drugs). He is a member of the Italian Association of Medical Oncology (AIOM), member of the AIOM Recommendations Committee on Thymic Epithelial Tumors (2020 edition), member of the AIOM Guidelines Writing Committee on Testis Tumors, member of the Directive Committee of the MEET-URO Italian Network, and present member of the Directive Committee AIOM (Regional - Lombardia). He is also a Member of the (EORTC) Group of thoracic tumors and Group of Uro- oncologic Tumors. Prof. Zucali is a founding partner, member of the steering committee, and co-coordinator of TYME (ThYmic MalignanciEs), the Italian clinical and research network on TETs (<https://www.tyme.eu/>). Within this consortium, he coordinates several clinical centers offering the best diagnostic procedures and clinical cares of TETs. TYME was founded in 2014 through a network of six institutions [Humanitas Research Hospital (Rozzano, Milan), Istituto Nazionale dei Tumori (Milan), Centro Riferimento Tumori Rari of "Federico II" University (Naples), Istituto Oncologico Veneto (Padua), Azienda Ospedaliera Universitaria Pisana (Pisa), Ospedali Riuniti (Ancona)]. TYME consortium has been greatly implemented over the past years and now included 31 centers covering the entire country and in which convey the Italian excellence in the field of clinical management of TETs. He co-coordinated the Italian Consensus Conference for the management of TETs (doi: 10.1016/j.ctrv.2018.10.001). He conceived and coordinated a multicenter phase II study of everolimus in patients with TETs previously treated with cisplatin-based chemotherapy (<https://doi.org/10.1200/JCO.2017.74.4078>), demonstrating that everolimus may be considered as a potential therapeutic option in patients with TETs (ESMO-NCCN guidelines). The Merck Investigator Studies Program Review Committee (MISP-RC) approved after an international selection (February 2019) his study proposal entitled: "Phase II Study Of Pembrolizumab + Carboplatin And Paclitaxel As First Line Chemotherapy In Patients With Locally Advanced/Metastatic Thymic Carcinoma" (PI: Dr. Paolo Andrea Zucali) for funding in the amount of Euro (€) 545,290 and drug supplies.

1. Perrino M, De Pas T, Bozzarelli S, Giordano L, De Vincenzo F, Conforti F, Digiacoio N, Cordua N, D'Antonio F, Borea F, Santoro A, Zucali PA. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. *Cancer*. 2022 Feb 15;128(4):719-726. PubMed PMID: 34706060.
2. Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F,

Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol.* 2021 Oct;22(10):1438-1447. PubMed PMID: 34499874.

3. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). *Cancer Treat Rev.* 2018 Dec;71:76-87. PubMed PMID: 30366202.
4. Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. *J Clin Oncol.* 2018 Feb 1;36(4):342-349. PubMed PMID: 29240542.

B. Positions, Scientific Appointments and Honors

Positions and Scientific Appointments

- | | |
|-------------|---|
| 2023 - | Director of the Residency Program in Medical Oncology., Humanitas University (HUNIMED), Pieve Emanuele (Milan) |
| 2020 - | Associate Professor of Medical Oncology, Department of Biomedical Sciences, Humanitas University (HUNIMED), Pieve Emanuele (Milan) |
| 2010 - | Head, Uroncological Tumors and Rare Tumors of the Chest Unit, Oncology and Hematology Department, IRCCS Istituto Clinico Humanitas, Rozzano (Milan) |
| 2008 - 2010 | Consultant in Medical Oncology, Medical Oncology and Hematology Unit, Oncology and Hematology Department, Istituto Clinico Humanitas, Rozzano (Milan) |
| 2002 - 2008 | Assistant in Medical Oncology, Medical Oncology and Hematology Unit, Oncology and Hematology Department, Istituto Clinico Humanitas, Rozzano (Milan) |

Honors

- | | |
|-------------|---|
| 2006 - 2006 | Recipient of the Associazione Italiana Oncologia Medica (AIOM) Translational Research Fellowship Award, Associazione Italiana Oncologia Medica (AIOM) |
|-------------|---|

C. Contribution to Science

1. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. No profit, multi center trial.
 - a. Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. *J Clin Oncol.* 2018 Feb 1;36(4):342-349. PubMed PMID: 29240542.
2. A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. No profit, multi center trial.
 - a. Perrino M, De Pas T, Bozzarelli S, Giordano L, De Vincenzo F, Conforti F, Digiacomo N, Cordua N, D'Antonio F, Borea F, Santoro A, Zucali PA. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. *Cancer.* 2022 Feb 15;128(4):719-726. PubMed PMID: 34706060.
3. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. No profit, multi center trial.
 - a. Conforti F, Zucali PA, Pala L, Catania C, Bagnardi V, Sala I, Della Vigna P, Perrino M, Zagami P, Corti C, Stucchi S, Barberis M, Guerini-Rocco E, Di Venosa B, De Vincenzo F, Cordua N, Santoro A, Giaccone G, De Pas TM. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and

thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2022 Oct;23(10):1287-1296. PubMed PMID: 36096156.